



Note - presentation notes may be read by double clicking on the icon to the left

# MHC II Haplotype Marker for Lumiracoxib Injury

Timothy M. Wright, MD

Global Head of Translational Sciences

**Recent Research Advances in Drug-Induced Liver Injury 2009**

April 8, 2009





# Drug Induced Liver Injury (DILI)

*Background (from FDA draft guidance October 2007)*

- Drug-induced hepatotoxicity has been the most frequent cause of safety-related marketing withdrawals for the past 50 years
- Most drugs withdrawn for severe DILI have rates for death and transplantation of  $\leq 1$  per 10,000
- Drugs that show severe DILI generally do not show signs of hepatotoxicity in animal models
- Laboratory measures of elevated aminotransferases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are used as the criteria for defining potential hepatotoxicity
  - $>3x$  upper limit of normal (ULN) suggest potential mild hepatocellular injury, while  $>5x$ ,  $>10x$ , and  $>15x$  ULN rates suggest increasing severity in hepatotoxicity
- Hy's law:  $>3x$  ULN ALT/AST **and**  $>2x$  ULN serum bilirubin
  - It is estimated that  $\sim 10\%$  Hy's law cases progress to death or liver transplantation



# Lumiracoxib Background

## ■ Mechanism of Action

- Selective COX-2 inhibitor
- Lumiracoxib has a favorable distribution (Rheumatoid Arthritis), with higher concentrations in the synovial fluid versus plasma 3 hours after dosing

## ■ Efficacy

- Efficacious for knee and hip osteoarthritis (OA, 100 mg qd)
- Highly efficacious in acute pain (e.g. dental pain, acute gout, dysmenorrhea, 400 mg qd)


## ■ Safety Benefits

- Favorable safety profile compared to non-selective COX-1/2 inhibitors:
  - GI benefit in non-aspirin users compared to ibuprofen or naproxen at 12 months
  - Effects on BP comparable to naproxen and slightly better than ibuprofen
- Incidence of CV events similar to NSAIDs (naproxen and ibuprofen)

## ■ Hepatic Safety

- Associated with reversible transaminase elevations and Hy's Law events during the development program
- Product labeling in countries where lumiracoxib was approved thus recommended monthly hepatic monitoring for chronic use
- Cases of liver failure and death associated with lumiracoxib were observed during post-marketing surveillance
- Lumiracoxib was not approved in the US

lumiracoxib





# Therapeutic Arthritis Research and Gastrointestinal Events Trial (TARGET)

- **52-week OA gastrointestinal clinical safety study to demonstrate that lumiracoxib (400 mg od) reduces the risk of developing complicated ulcers compared to NSAIDs (naproxen 500 mg bid and ibuprofen 800 mg tid)**
  - Comprised of two trials CCOX189 0117 and CCOX189A2332 with identical study design using different comparator therapies (ibuprofen & naproxen)
  - 18,244 patients randomized (9,117 to lumiracoxib, 4,730 to naproxen, 4,397 to ibuprofen)
  - 10,057 consented DNA samples obtained
- **Trial Results:**
  - 79% reduction in upper GI ulcer complications was observed with lumiracoxib as compared to studied NSAIDs in non-aspirin population
  - No statistical difference in incidences of CV events between lumiracoxib and NSAIDs at 12 months
  - Higher proportion of >3xULN ALT/AST elevations seen for lumiracoxib-treated patients (2.6%) compared to NSAIDs (0.6%)

# Stage 1: Genome-wide Association Study Design

*>5xULN ALT/AST patients from TARGET*

## ■ Case/control design

- Initial pharmacogenetic analysis of 41 lumiracoxib recipients with ALT/AST >5xULN (with DNA and informed consent)
- Selected 176 controls matched ~4:1 to cases based on clinical trial, sex, race, age ( $\pm 2$  years), and, where possible, country
- Patients that were adjudicated by the liver safety committee to not be drug-related were removed from the analysis

## ■ Genome-wide analysis

- Analyzed only SNPs on Affymetrix array 6.0

## ■ Statistical methods

- Association test performed individually for each SNP using Cochran-Mantel-Haenszel (CMH) test
- Permutation test applied to adjust for multiple testing across SNPs
- PLINK software (Shaun Purcell, MGH)





# Human Genome Variability

- 3 billion nucleotides (A, T, G, or C) and ~20-25,000 genes
- For any 2 people 99.9% of those nucleotides are identical
- Remaining differences 0.1% are responsible for the genetic contribution to inter-individual differences:
  - appearance, abilities, response to environment, disease susceptibility, drug responses, etc.
- ~10 million common **Single Nucleotide Polymorphisms (SNPs)** exist in the human population
- SNPs frequently occur in haplotypes: contiguous blocks of SNPs inherited together
- SNPs are the most common type of variation; however, other types also exist: insertion/deletions, copy number variation, short tandem repeats






# Single Nucleotide Polymorphism (SNP) Definition

- **Change in one nucleotide**
- **Most frequent type of variation**
- **On average, occur every few hundred nucleotides**

TCTTTGTATA	TCATCTTCCA	TAATTCAAAT	<b>T</b> ATTAATACT	GAAATTATAA
TCTTTGTATA	TCATCTTCCA	TAATTCAAAT	<b>C</b> ATTAATACT	GAAATTATAA
TCTTTGTATA	TCATCTTCCA	TAATTCAAAT	<b>T</b> ATTAATACT	GAAATTATAA
TCTTTGTATA	TCATCTTCCA	TAATTCAAAT	<b>C</b> ATTAATACT	GAAATTATAA
TCTTTGTATA	TCATCTTCCA	TAATTCAAAT	<b>C</b> ATTAATACT	GAAATTATAA
TCTTTGTATA	TCATCTTCCA	TAATTCAAAT	<b>T</b> ATTAATACT	GAAATTATAA

  
**T to C variation**



# Advances in SNP Array Technology

*~100x resolution enhancement in the past 5 years*

- Affymetrix 1.5K Array
- 10K (*113 kb median intermarker distance*) 2003\*
- 100K, 2005\*
- 500K (*2.5 kb median intermarker distance*) 2006\*
- SNP Array 5.0; 500K SNPs, 400K copy number probes
- SNP Array 6.0; >900K SNPs, 940K copy number probes (*<700 bases median intermarker distance*) 2008\*




\* First publications using these Arrays



# Genome-wide Association Results for All SNPs

*p-values Plotted by Genomic Location; >5xULN ALT/AST*



# Genome-wide Results >5xULN ALT/AST Patients

- Significant findings from the exploratory genome-wide association study after multiple testing corrections

rs number	Chromosome	Region	Position	Nominal p-value	Study-wide p-value
rs9270986	6	MHC	32682038	$2.8 \times 10^{-10}$	0.0075
rs3129900	6	MHC	32413957	$1.8 \times 10^{-9}$	0.022
rs3132943	6	MHC	32416443	$1.9 \times 10^{-9}$	0.023
rs3129934	6	MHC	32444165	$2.5 \times 10^{-9}$	0.026
rs3135365	6	MHC	32497233	$4.5 \times 10^{-9}$	0.038
rs3129932	6	MHC	32444105	$6.5 \times 10^{-9}$	0.047
rs910049	6	MHC	32423705	$6.6 \times 10^{-9}$	0.047



# Stage 2: Pharmacogenetic Replication Study Design

- **Additional TARGET trial samples used**
- **Case/control design**
  - Analyzed 98 independent lumiracoxib patients with ALT or AST >3xULN (with DNA and consent)
  - Selected 405 controls matched ~4:1 to cases based on clinical trial, sex, race, age ( $\pm 2$  years), and, where possible, country.
- **Evaluated 13 SNPs in replication analysis (most from the MHC region)**
  - 6 SNPs are from the MHC class II region, 2 from a distal MHC region, 1 from a DME, 2 from the top non-MHC SNPs, and 2 from other chromosomes
- **Secondary analysis: recipients of comparator therapy**
  - Analyzed 18 ibuprofen recipients and 9 naproxen recipients with ALT or AST >3xULN (with DNA and consent)
  - Selected control samples for each comparator therapy
    - Controls matched ~4:1 to cases based on above criteria



# Stage 2: Replication Study Results

*Data from independent samples*

rs number	Gene/ region	p-value	Carrier <sup>1</sup> case frequency	Carrier <sup>1</sup> control frequency	MAF <sup>2</sup> cases	MAF <sup>2</sup> controls
3129900	MHC	<b>4.4x10<sup>-12</sup></b>	61.2%	27.3%	36.7%	14.8%
3129934	MHC	<b>4.9x10<sup>-11</sup></b>	61.1%	27.6%	36.3%	14.9%
3135365	MHC	<b>6.3x10<sup>-10</sup></b>	66.3%	33.8%	39.8%	18.8%
9270986	MHC	<b>1.0x10<sup>-9</sup></b>	59.8%	26.9%	34.5%	14.8%
9275772	MHC	<b>2.6x10<sup>-6</sup></b>	58.2%	35.7%	36.2%	20.7%
3130952	MHC	<b>4.5x10<sup>-4</sup></b>	36.5%	21.9%	21.4%	11.9%
2517451	MHC	0.0018	27.8%	16.6%	15.5%	8.5%
2517538	MHC	0.08	69.5%	62.0%	45.8%	38.6%
10509681	CYP2C8	0.099	26.0%	18.1%	14.1%	9.8%
2123139	chr. 11	0.48	8.4%	10.9%	4.2%	5.5%
2577302	FN1	0.47	8.2%	6.4%	4.1%	3.2%
7131977	ALDH1L2	0.56	14.4%	11.9%	7.2%	6.2%
9659646	chr. 1	0.66	2.1%	1.5%	1.0%	0.8%

<sup>1</sup>Carriers are defined as having either 1 or 2 copies of the allele. <sup>2</sup>MAF= minor allele frequency




## Stage 2: Replication Study Results Summary

- Top Stage 1 SNPs in MHC Class II region were highly significant in Stage 2 (best nominal  $p= 4.4 \times 10^{-12}$ )
  - Provides clear evidence of replication
- No SNPs in other genes showed evidence of association
- No SNPs showed significant evidence of association in ibuprofen, naproxen, or combined arms
  - Sample sizes are too small for definitive conclusions for comparator arms



# Stage 3: HLA<sup>1</sup> Allele Identification

- Evaluate whether top SNP(s) may be tagging a potentially causative classical MHC<sup>2</sup> allele/haplotype
  - May improve predictive capability
  - May provide insight into mechanism
- Case/control design using all >3xULN patients (137 cases & 577 controls) from TARGET for which DNA was available
- HLA genes evaluated (all from MHC Class II region)
  - DRB1, DRB3, DRB4, DRB5, DQA1, and DQB1



<sup>1</sup>HLA=Human Leukocyte Antigens, <sup>2</sup>MHC=Major Histocompatibility Complex



# HLA Results for All TARGET Liver Cases

*(with DNA available)*

<b>Gene/allele</b>	<b>p-value</b>
DRB1*1501	$6.8 \times 10^{-25}$
DQB1*0602	$1.1 \times 10^{-22}$
DRB5*0101	$1.6 \times 10^{-20}$
DQA1*0102	$1.2 \times 10^{-18}$

- DRB1\*1501-DQA1\*0102-DQB1\*0602-DRB5\*0101 are part of a very well-characterized haplotype
  - Also associated with an increased risk for developing multiple sclerosis
  - Associated with amoxicillin-clavulanate induced hepatotoxicity



# Performance Characteristics of HLA-associated Alleles

*Lumiracoxib-treated patients with >3xULN ALT/AST*

Gene/allele	Sensitivity	Specificity	PPV	NPV	RR	Allele frequency case/control
DRB1*1501	64.2%	80.8%	8.3%	98.82%	7.0	35.4%/10.5%
DQB1*0602	62.0%	80.8%	8.0%	98.74%	6.4	34.3%/10.5%
DRB5*0101	64.2%	80.1%	8.0%	98.81%	6.7	32.1%/10.0%
DQA1*0102	73.7%	69.2%	6.1%	<b>98.98%</b>	6.0	42.7%/17.4%

Patients carrying at least one copy of the risk allele are considered to have the risk genotype.  
Overall TARGET lumiracoxib-treated study event-free rate for >3xULN is **97.37%**

RR= relative risk

PPV= positive predictive value

NPV= negative predictive value



# Performance Characteristics of HLA-associated Alleles

## *Lumiracoxib-treated patients with >5xULN ALT/AST*

Gene/allele	Sensitivity	Specificity	PPV	NPV	RR	Allele frequency case/control
DRB1*1501	77.0%	80.8%	4.9%	99.64%	13.5	41.0%/10.2%
DQB1*0602	72.1%	80.0%	4.4%	99.56%	9.9	38.5%/10.8%
DRB5*0101	77.0%	79.6%	4.6%	99.63%	12.5	38.5%/10.2%
DQA1*0102	83.6%	68.2%	3.3%	<b>99.69%</b>	10.6	48.4%/17.6%

Patients carrying at least one copy of the risk allele are considered to have the risk genotype.

Overall TARGET lumiracoxib-treated event-free rate for >5xULN is **98.74%**

RR= relative risk, PPV= positive predictive value, NPV= negative predictive value

- The DQA1\*0102 allele performs the best as a predictive marker and was thus further characterized



# DQA1\*0102 Marker Sensitivity Improves with Increasing Thresholds of ALT/AST Elevation

Sensitivity and number of cases with DQA1\*0102 allele

<b>ALT/AST (fold &gt;ULN)</b>	<b>Sensitivity</b>	<b>Number of cases with DQA1*0102 allele</b>	<b>Total number of genotyped cases</b>
>3x	73.7%	101	137
>5x	83.6%	51	61
>8x	90.9%	30	33
>10x	91.7%	22	24
>15x	93.8%	15	16
>20x	100%	8	8



# HLA Genotypes for Hy's Law Cases (n=3)


Hy's law case	DRB1*1501	DQA1*0102	DRB5*0101	DQB1*0602
Patient 1	Carrier	Carrier	Carrier	Carrier
Patient 2	Carrier	Carrier	Carrier	Carrier
Patient 3	Carrier	Carrier	Carrier	Non-carrier (carrier for *0601 allele)

- In TARGET, of the 9 lumiracoxib Hy's cases, 5 did not provide DNA or consent for PG analysis. The 6<sup>th</sup> failed quality control standards.



# Mean peak ULN ALT/AST levels suggest carrier<sup>1</sup> and non-carrier cases have differences in severity of hepatotoxicity

Mean peak ULN ALT/AST levels of cases (>3xULN) for DQA1\*0102 carriers<sup>1</sup> and non-carriers



<sup>1</sup>Carriers are defined as having either 1 or 2 copies of the DQA1\*0102 allele



## DQA1\*0102 carriers vs. non-carriers<sup>1</sup> show different frequencies of liver injury type for >3xULN ALT/AST cases


Type of liver injury	Carrier <sup>1</sup>	Non-carrier
Hepatocellular	76 (76.0%)	17 (47.2%)
Mixed	21 (21.0%)	17 (47.2%)
Cholestatic	3 (3.0%)	2 (5.6%)
Total	100	36

p=0.0015

<sup>1</sup>Carriers are defined as having either 1 or 2 copies of the DQA1\*0102 allele



# Kaplan-Meier Incidence Estimates (%) for >3xULN ALT/AST Elevations (weeks 13, 26, 39, and 52) for TARGET



Carriers are defined as having either 1 or 2 copies of the DQA1\*0102 allele





# Summary of Results

1 of 2

- **Genome-wide association study of 41 cases (>5xULN ALT/AST) and 176 matched controls identified a significant association to the MHC class II region (top SNP  $p=2.8 \times 10^{-10}$ , genome-wide  $p=0.0075$ )**
- **Findings were replicated in an independent set of 98 cases (>3xULN ALT/AST) and 405 matched controls (top SNP  $p=4.4 \times 10^{-12}$ )**
- **HLA fine mapping identified a highly significant association to a well characterized haplotype (>3xULN ALT/AST cases  $n=137$ , controls  $n=577$ )**

Gene/allele	p-value
DRB1*1501	$6.8 \times 10^{-25}$
DQB1*0602	$1.1 \times 10^{-22}$
DRB5*0101	$1.6 \times 10^{-20}$
DQA1*0102	$1.2 \times 10^{-18}$



- **DQA1\*0102 allele used as a predictive marker would have a sensitivity of 73.7% and an NPV of 98.98% for >3xULN ALT/AST (overall population event-free rate is 97.37%)**
- **The DQA1\*0102 marker sensitivity improves with increasing ULN thresholds, and 3 of 3 Hy's law cases carry the risk allele**
- **Kaplan-Meier estimates show that lumiracoxib 400mg qd DQA1\*0102 non-carrier patients have similar incidence estimates for both >3xULN and >5xULN ALT/AST as ibuprofen-treated patients**
- **Further exploratory analysis failed to clearly identify additional hepatotoxicity markers**



# Drug-related SAEs Associated with HLA Genes

- HLA-B\*1502 with Stevens-Johnson syndrome and toxic epidermal necrolysis after carbamazepine treatment (Asians)
- DRB1\*07/DQA1\*02 is associated with hepatotoxicity after ximelagatran (Exanta) treatment
- DRB1\*1501-DQA1\*0102-DQB1\*0602-DRB5\*0101 is associated with amoxicillin-clavulanate induced hepatotoxicity
- HLA-B\*5701 is associated with abacavir hypersensitivity
- DRB1\*1302 and DQB1\*0604 was found to be associated with ticlopidine hepatotoxicity (Japanese)




# MHC Association with Hepatotoxicity

## *Potential Insights into DILI Pathogenesis*

- Drug or metabolite may act as “hapten” binding to a self protein/peptide that is presented by MHC molecule(s) and recognized as foreign
- Specificity for binding “modified” peptide may be restricted to individuals bearing only a limited number of MHC alleles
- Restriction by human MHC Class II may explain lack of predictability of animal toxicology studies for human hepatotoxicity – inbred animal strains are homozygous for a single MHC haplotype; evolutionary differences in peptide binding specificity across species



# MHC-Peptide TCR Structure



[http://www.bmb.psu.edu/faculty/tan/lab/gallery\\_proteins.html](http://www.bmb.psu.edu/faculty/tan/lab/gallery_proteins.html)



# Acknowledgements

---

- S Lewitzky, J Singer, C Paulding, N Nirmala, J Meyer - Biomarker Development
- L Klickstein -Translational Medicine
- Gabriel Helmlinger - Modeling and Simulation
- Patrice Matchaba – Drug Safety and Epidemiology
- The Prexige Global Project Team
- Participants and Investigators of the TARGET study